Results 161 to 170 of about 62,343 (221)

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial. [PDF]

Vaccines (Basel)
Xie Z, Li J, Wang X, Huang L, Gou J, Zhang W, Huang H, You W, Wang F, Li X, Zhang J, Han Q, Ma X, Wang Y.   +13 more
europepmc   +1 more source

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults. [PDF]

Infect Dis Ther
Rey-Ares L, Averin A, Mac Mullen M, Hariharan D, Atwood M, Carballo C, Huang L.   +6 more
europepmc   +1 more source

Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia. [PDF]

Nat Commun
von Mollendorf C, Mungun T, Ulziibayar M, Skoko P, Boelsen L, Nguyen C, Batsaikhan P, Suuri B, Luvsantseren D, Narangerel D, Tsolmon B, Demberelsuren S, Ortika BD, Pell CL, Wee-Hee A, Nation ML, Hinds J, Dunne EM, Mulholland EK, Satzke C.   +19 more
europepmc   +1 more source

Radiographically confirmed pneumonia in Malawian children and associated pneumococcal carriage after introduction of the 13-valent pneumococcal conjugate vaccine. [PDF]

Pneumonia (Nathan)
Mzumara G, Chirombo J, Swarthout TD, Bar-Zeev N, Harawa PP, Jalloh MS, Kirolos A, Mukhula V, Newberry L, Ogunlade O, Wachepa R, French N, Heyderman RS, Iroh Tam PY.   +13 more
europepmc   +1 more source

Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine

, 2001
Mercedes Pérez‐Melgosa, Hans D. Ochs, Peter S. Linsley, Jon D. Laman, Marjan van Meurs, Richard A. Flavell, Robert K. Ernst, Samuel I. Miller, Christopher B. Wilson   +8 more
openalex   +1 more source

A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015. [PDF]

BMC Infect Dis
Yen TA, Wu JL, Wang CC, Huang LY, Yeo SH, Patel D, Lim CTK, Lin HW, Yamada E, Sukarom I.   +9 more
europepmc   +1 more source

Factors Influencing Vaccine Receipt During a 2018 Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India. [PDF]

Am J Trop Med Hyg
Borhade P, LeBoa C, Jayaprasad N, Date K, Haldar P, Harvey P, Shimpi R, An Q, Zhang C, Horng L, Fagerli K, Yewale VN, Daruwalla S, Dharmapalan D, Gavhane J, Joshi S, Rai R, Rathod V, Shetty K, Warrier DS, Yadav S, Chakraborty D, Bahl S, Katkar A, Kunwar A, Andrews JR, Bhatnagar P, Dutta S, Luby SP, Hoffman SA.   +29 more
europepmc   +1 more source

Safety and Immunogenicity of a Conjugate Vaccine againstHaemophilus influenzaeType b in Splenectomized and Nonsplenectomized Patients with Cooley Anemia

, 2001
Rolando Cimaz, Carolina Mensi, Emanuela D’Angelo, Elisabetta Fantola, Vittoria Milone, Luigi Roberto Biasio, V. Carnelli, Alessandro Zanetti   +7 more
openalex   +1 more source

Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. [PDF]

MMWR Morb Mortal Wkly Rep
Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, Schechter R, Poehling KA, Long SS, Loehr J, Cohen AL.   +10 more
europepmc   +1 more source

Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age. [PDF]

Hum Vaccin Immunother
Robertson CA, Jacqmein J, Selmani A, Galarza K, Oster P.   +4 more
europepmc   +1 more source